University of Illinois at Chicago Medical Center UIC College of Pharmacy Burr Ridge, Illinois
Navigating best practices in the pharmacological management of breast cancer is increasing in complexity. New data is constantly emerging, rapidly changing the standard of care. This presentation will focus on evaluating breast cancer patient cases related to HER2 expression in metastatic disease, the application of immune checkpoint inhibitor therapy in early-stage triple negative disease, and the evolving treatment landscape of high-risk hormone receptor-positive early breast cancer. Unique clinical and managed care perspectives around specific patient cases will be discussed, along with developing clinical trial data.
Learning Objectives:
Identify optimal strategies for the treatment of early-stage and metastatic breast cancer
Investigate recent clinical updates evaluating breast cancer therapies and subsequent implications for changes in practice paradigms
Analyze the impact of new data on clinical and managed care considerations for enhancing care for patients with breast cancer